Provectus Biopharmaceuticals Net Tangible Assets

As of the most recent data (June 2026), PVCT shows a net tangible assets of $-6.3M. That compares with $-5.9M in the prior-year period — down 7.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PVCT's net tangible assets is now $-6.3M (was $-5.9M) — a 7.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Provectus Biopharmaceuticals is outperforming or lagging.

Tracking PVCT's net tangible assets over time shows whether Provectus Biopharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $-6.3M That compares with $-5.9M in the prior-year period — down 7.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net tangible assets page, Stockcircle has Provectus Biopharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $-6.3M) with ownership activity and broader fundamentals.

Provectus Biopharmaceuticals's net tangible assets is $-6.3M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.